Agenus Appoints José Iglesias as Chief Medical Affairs Officer to Lead Global Medical Affairs and Early-Access Programs, Including France's AAC

Agenus Inc. has appointed José Iglesias, M.D. as Chief Medical Affairs Officer to oversee global medical affairs and early-access programs for its immuno-oncology treatments. Iglesias will lead the development of BOT/BAL, a combination of CTLA-4 and PD-1 antibodies being investigated in microsatellite-stable colorectal cancer. He will guide global medical affairs strategy, medical evidence generation, and appropriate use within regulatory and early-access frameworks worldwide.